HONG KONG, Sept. 6, 2011/PRNewswire-Asia/ -- Golden Meditech Holdings Limited ("Golden Meditech", together with its subsidiaries collectively as the "Group", - 801.HK; 910801.TW), which embodies a leading medical devices enterprise, a major brand name in haematology hospital and the largest stem cell cord blood banking operator in China, is pleased to announce the launch of its Taiwan representative office today.
With a track record in China for establishing the largest stem cell cord blood banking corporation, developing a premium hospital service business, and now, building a cross-straits healthcare enterprise, Mr. Kam Yuen, Chairman and CEO of Golden Meditech, in known as a pioneer in China's healthcare industry. With his remarkable insights and ability to stay ahead of industry trends while having the attention and tenacity as an entrepreneur, Mr Kam has set his sight on the substantial opportunities in Taiwan's medical and bio-tech industries. The Group has already set foot in Taiwan via issuing Taiwan Depositary Receipts ("TDR") on the Taiwan Stock Exchange in January 2011. Mr. Kam is of the view that the launch of Economic Cooperation Framework Agreement ("ECFA") and the policy allowing for easier access between the straits will foster the development of premium healthcare service sector. Whereas Taiwan has readily accessible medical expertise and resources, with the launch of the new Taiwan representative office, the Group will be able to better leverage its operative advantage, expand its industry reach and create greater opportunities with its Taiwan counterpart for greater growth.
Golden Meditech is the first and one the largest blood-related medical device manufacturer in China with its key product, the Autologous Blood Recovery System ("ABRS") accounting for 80% share of the top-tier hospital market. China's ongoing medical reform has created an excellent opportunity for the Group as a pioneer in the areas of hospital services and hospital management. The Group's hospital management business is the first wholly-owned foreign entity to provide nation-wide hospital management services in China while its specialist haematology hospitals, operated under the "Daopei Hospital" brand, is a name to be reckoned in its specialty. Just recently, the Group has acquired a reputable operation, the Shanghai East International Medical Centre in Shanghai, to further strengthen its strategic position as a premium medical service provider
The Group's healthcare service portfolio also includes the first dedicated medical insurance information process and claims settlement business process outsourcing (BPO) service provider, GM Medicare Company Limited, launched in April 2011, and a stake in China Cord Blood Corporation ("CCBC"; NYSE listed stock code CO:US), the largest cord blood banking operator in China and a major shareholder of CORDLIFE LTD, a leading pan-Asian cord blood bank operator.
China's medical reform will be a key focus in the Twelve National People's Congress's Five-Year-Plan. The Group's healthcare services business will be a key beneficiary of the reform and a key growth driver to its growing business operations. Mr. Kam believes the progressive nature of the new medical reform and the ECFA has orchestrated the perfect opportunity for healthcare enterprises across the straits to form strategic partnerships and create a platform to connect and leverage on each other's strengths and capabilities. Golden Meditech maintains a positive outlook on Taiwan's healthcare industry, as the Group anticipates new opportunities for growth and collaboration with its ample resources in experience and competitive advantages. As it expands it foothold in Taiwan, the Group is also looking forward to identify suitable management talents and medical professions with its Taiwanese partners for even greater achievements In the future.
About Golden Meditech Holdings Limited
Golden Meditech Holdings Limited is China's leading integrated-healthcare devices and service operator, and the first medical device enterprise that was publicly listed outside of the PRC on the Stock Exchange of Hong Kong Limited (HKEx) and the Taiwan Stock Exchange (TSE). Golden Meditech is a first-mover in China, having established dominant positions in medical devices and healthcare services markets over the years, thanks to its strengths in innovation and market expertise and the ability to capture emerging market opportunities. Going forward, the Group will continue to pursue a leading position in China's healthcare industry both through organic growth and strategic expansion.
For more information, please contact:
Investor Relations Department
Golden Meditech Holdings Limited
Address: 48/F, Bank of China Tower, 1 Garden Road, Central, Hong Kong
Tel: +852-3605-8180
Fax: +852-3605-8181
Email: ir@goldenmeditech.com
